Moleculin Other Current Liab from 2010 to 2025

MBRX Stock  USD 1.27  0.01  0.79%   
Moleculin Biotech Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2025. During the period from 2010 to 2025, Moleculin Biotech Other Current Liabilities regression line of annual values had r-squared of  0.78 and arithmetic mean of  1,623,579. View All Fundamentals
 
Other Current Liabilities  
First Reported
2015-09-30
Previous Quarter
2.8 M
Current Value
2.9 M
Quarterly Volatility
1.6 M
 
Yuan Drop
 
Covid
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Depreciation And Amortization of 108.6 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.92. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
  
Check out the analysis of Moleculin Biotech Correlation against competitors.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Latest Moleculin Biotech's Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Moleculin Biotech over the last few years. It is Moleculin Biotech's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
164.1.7M2.2M2.6M4.2M4.8M5.1M920%29%21%62%15%5%100%
       Timeline  

Moleculin Other Current Liab Regression Statistics

Arithmetic Mean1,623,579
Geometric Mean582,096
Coefficient Of Variation111.01
Mean Deviation1,483,566
Median1,405,000
Standard Deviation1,802,314
Sample Variance3.2T
Range5M
R-Value0.88
Mean Square Error766.8B
R-Squared0.78
Slope334,268
Total Sum of Squares48.7T

Moleculin Other Current Liab History

20255.1 M
20244.8 M
20234.2 M
20222.6 M
20212.2 M
20201.7 M
2019164 K

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities4.8 M5.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…